Delivery Order SPE2DR25D2206-SPE2DR26F9AA7
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets in a 90-count quantity. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $28,009.13 and is scheduled for completion by September 10, 2025. The contract represents a single line item fulfillment under AmerisourceBergen's existing pharmaceutical supply vehicle with DLA, with performance to occur...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity, with a ceiling value of $1,867.39. This firm fixed-price delivery order has an ultimate completion date of October 28, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award utilized no set-aside designation, indicating it was competitively awarded among...
- The Defense Logistics Agency awarded a delivery order valued at $2,934.36 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) on September 16, 2025. This firm fixed price delivery order, with a completion date of September 17, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. The pharmaceutical product...
- The Defense Logistics Agency awarded a $2,851.36 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity. This competitively awarded, firm fixed-price contract is categorized as a delivery order with an ultimate completion date of September 17, 2025, and carries no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,456.18 delivery order on August 14, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count). This competitive award utilized firm fixed price contracting with no set-aside designation and an ultimate completion date of August 15, 2025. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-day supply, with a ceiling value of $6,402.24. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. The contract has an ultimate completion date of September 15, 2025, with performance at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) with a ceiling value of $3,929.59. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of October 31, 2025. This delivery order is a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 24, 2025, for the supply of Losartan-HCTZ 100-25 mg tablets (90-count) with a ceiling value of $2,277.71. This is a firm fixed-price delivery order with no set-aside designation, competed openly, and is scheduled for completion by June 25, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of 1,000 tablets of Losartan-HCTZ 100-25 mg, a combination antihypertensive medication. This firm fixed-price delivery order, valued at $14,016.98, is scheduled for completion by November 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement and is issued as a child delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,491.29 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's corporate headquarters location. The delivery order represents a child...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9AA7Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets in a 90-count quantity. This firm fixed-price delivery order, valued at $19,522.44, represents a non-competitive, non-set-aside award with an ultimate completion date of November 4, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of medications and medical supplies to military healthcare systems globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor serving defense and healthcare procurement needs across the Department of Defense and related agencies. The company's extensive federal contract portfolio demonstrates its capability to fulfill complex medical supply requirements through competitive procurement processes. As a child contract under the DLA's broader pharmaceutical prime vendor program, this delivery order exemplifies the company's role in supporting military and veteran healthcare systems through the reliable supply of essential medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.5k | 11/3/25 |